131279Development of a new class of bacterial resistance inhibitors for the treatment of multi-drug resistant infectionClosedFeasibility StudiesInnovate UKThe spread of multi-drug resistance (MDR) threatens to change the face of health care worldwide, crippling hospital units that rely on the ability to control infections in patients with weakened immune systems. We risk returning to a "pre-antibiotic" era unless we can develop new approaches to tackling bacterial resistance. Blueberry Therapeutics aims to assess the feasibility of an innovative therapeutic approach to inhibit key mechanisms of MDR using peptide aptamers formulated with a new nanoparticle delivery system. By directly targeting the mechanisms of resistance we hope to reverse bacterial resistance and render drug resistant bacteria sensitive to treatment with already available and common antibiotics again. We aim to demonstrate the feasibility of this approach to restore antibiotic sensitivity in clinically relevant MDR bacterial species and if successful will be the first step in developing a new class of therapies with which to treat MDR infections.